Guidance Revision, Recent Survey and PharmaLab Pre-Conference

Aberrant analytical results are a recurring challenge in pharmaceutical quality control laboratories. A clear distinction between Out-of-Specification (OOS), Out-of-Expectation (OOE), and Out-of-Trend (OOT) results is essential for GMP-compliant and inspection-ready investigations. Although FDA and MHRA guidance has been available for many years, practical implementation continues to vary.

According to the FDA’s Guidance for Industry on OOS results, issued in May 2022, “the term OOS results includes all test results that fall outside the specifications or acceptance criteria established in drug applications, drug master files (DMFs), official compendia, or by the manufacturer. The term also applies to all in-process laboratory tests that are outside of established specifications.”

The OOS investigation follows a structured approach. The initial laboratory assessment considers potential assignable causes, including sample handling, dilution or calculation errors, transcription mistakes, equipment problems, reagents, standards, and raw data. If a documented laboratory cause is established, the suspect result may be invalidated and replacement testing may be justified.

An OOE result is an atypical result that meets specification but falls outside the expected variability of the analytical procedure. It should prompt a documented, risk-based assessment and, where appropriate, a hypothesis-based investigation. An OOT result is a time-dependent result outside a prediction interval or in breach of a statistical process-control criterion. The assessment must distinguish between process data for which no systematic time trend is expected and stability data for which a trend is scientifically expected.

The ECA Analytical Quality Control Group (AQCG) has developed practical documents on OOS and OOE/OOT results. Both documents are currently being revised. To support the guidance revision, the AQCG conducted an industry survey from February to April 2026, receiving 169 responses. Basic principles are widely established: 91% of respondents clearly define OOS results, 89% distinguish between OOS, OOT, and invalid results, and second-person reviews are common. Further development is needed in hypothesis testing and root-cause analysis. Respondents requested decision trees, practical examples, and harmonised approaches, particularly for biologics, non-chromatographic methods, and contract laboratories. Microbiology requires additional consideration of Out-of-Limit (OOL) results in environmental monitoring and is addressed in separate guidance.

The revised OOE/OOT Guidance is expected to expand its treatment of normally distributed analytical data and to bring together Shewhart charts, including X-bar, range, and standard-deviation charts, as well as CUSUM, EWMA, control charts for discrete data, process-capability analysis, and stability trend limits based on linear and random-coefficients regression.

The revised documents and survey results will be presented at the PharmaLab Congress in Darmstadt during the pre-conference “Data Quality Management of Aberrant Results” on 23 November 2026. The programme includes regulatory fundamentals, trend analysis, biopharmaceutical applications, an Excel workshop on statistical out-of-control rules, and a Q&A session. The event is aimed at laboratory and QC managers, Qualified Persons, analysts, and CMO/CRO personnel. Details are available at http://www.pharmalab-congress.com/dqm-ar.

Independently of participation at PharmaLab 2026, AQCG members may consult and download the documents in the members’ area. Further information is available at https://analytical.gmp-compliance.org, where interested professionals can also apply for free membership.